| ISPC 0.1365 17.17% | CTNT 0.0953 -40.73% | BYND 0.8226 5.19% | YXT 0.496 34.05% | TZA 5.08 -6.45% | EFOI 6.49 210.53% | TSLL 13.9 6.35% | NVDA 201.68 1.68% | BITO 10.63 2.71% | NFLX 97.31 -9.72% | INTC 68.5 0.00% | ZSPC 0.0536 -38.46% | TQQQ 58.59 3.83% | SOXS 18.87 -6.95% | TSLA 400.62 3.01% | XLE 55.02 -2.76% | AMC 1.86 15.53% | SCO 8.47 9.72% | PLUG 2.78 -2.80% | BMNG 1.6 4.58% | IBIT 43.94 2.83% | AAL 12.78 4.16% | BZAI 2.52 45.66% | CRML 12.56 35.49% | SOFI 19.43 2.10% | HIVE 2.51 14.87% | GRAB 4.21 4.73% | SPY 710.14 1.21% | SQQQ 56.39 -3.79% | SOXL 94.68 7.14% | SMR 12.65 10.87% | BMNR 22.95 2.27% | SNAP 6.03 0.17% | UCAR 1.49 29.57% | HIMS 28.82 6.78% | LZMH 0.1736 -84.07% | HYG 80.65 0.37% | DRIP 5.25 9.83% | ONDS 10 -1.96% | DVLT 0.758 -9.49% | AAPL 270.23 2.59% | QQQ 648.85 1.31% | MARA 11.6 0.43% | MSTR 166.52 11.80% | AMZN 250.56 0.34% | PLTR 146.39 2.54% | SPDN 9.13 -1.19% | PBM 7.6 29.47% | IONQ 46.09 3.16% | MSFT 422.79 0.60%

JPMorgan Upgrades Kodiak Sciences To Neutral, Sees Catalyst-Heavy Period Ahead

JPMorgan upgraded Kodiak Sciences (NASDAQ:KOD) from Underweight to Neutral and set a December 2026 price target of $15.00.

The bank said Kodiak is entering a catalyst-rich period over the next two years, with pivotal trial data expected for tarcocimab, KSI-501, and KSI-101. While acknowledging that valuation is not a barrier to a more positive stance, JPMorgan noted that investor sentiment remains mixed and that clear clinical wins may be required to shift views more favorably.

The firm sees Kodiak shares performing in line with the broader biotech sector until further clarity emerges from these upcoming data releases.

Published on: August 14, 2025